Acetyl Gastric Inhibitory Peptide (human)_product_DataBase

Bioactivity	Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity[1][2][3].
Invitro	Acetyl Gastric Inhibitory Peptide (human) induces cyclic adenosine 3'5' monophosphate (cAMP) production with an EC50 value of 1.9 nM in Chinese hamster lung fibroblast cells transfected with the human GIP receptor[1].Acetyl Gastric Inhibitory Peptide (human) (10-13-10-8 nM) shows potent effect at stimulating insulin release compared to the native GIP in BRIN-BD11 cells[1].Acetyl Gastric Inhibitory Peptide (human) improves glucose intolerance, type 2 diabetes, beta-cell glucose insensitivity, insulin resistance and reduced insulin secretion[2].Acetyl Gastric Inhibitory Peptide (human) has metabolic stability and hypoglycemic and insulin modulating activities of two fatty acid derivatized N-terminally acetylated GIP analogs were evaluated in in vitro and in vivo[3].
Name	Acetyl Gastric Inhibitory Peptide (human)
CAS	299898-33-2
Shortening	Ac-YAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ
Formula	C228H340N60O67S
Molar Mass	5025.60
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.

PeptideDB